Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial

Jaewon Yang, Won Myong Bahk, Hyun Sang Cho, Yang Whan Jeon, Duk In Jon, Hee Yeon Jung, Chan Hyung Kim, Hee Cheol Kim, Yong Ku Kim, Young Hoon Kim, Jun Soo Kwon, Sang Yeol Lee, Seung Hwan Lee, Jung Seo Yi, Bo Hyun Yoon, Seung Hyun Kim

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objectives: The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. Methods: Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. Results: Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was-23.48 ± 19.73 for the blonanserin group and-25.40 ± 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and increased level blood prolactin (P = 0.0012). On the other hand, the adverse events that occurred more frequently in the blonanserin than in the risperidone group was hand tremor (P = 0.0006). Conclusions: Blonanserin was effective in the treatment of Korean patients with schizophrenia compared with risperidone and was more tolerable with a better safety profile, particularly with respect to prolactin elevation. These findings suggest that blonanserin is useful in the treatment of schizophrenia.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalClinical Neuropharmacology
Volume33
Issue number4
DOIs
Publication statusPublished - 2010 Jul 1

Fingerprint

Risperidone
Schizophrenia
Prolactin
Safety
blonanserin
Dysarthria
Vital Signs
Dizziness
Tremor
Therapeutics
Aspartate Aminotransferases
Alanine Transaminase
Physical Examination
Hand

Keywords

  • blonanserin
  • efficacy
  • schizophrenia
  • tolerability

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Efficacy and tolerability of blonanserin in the patients with schizophrenia : A randomized, double-blind, risperidone-compared trial. / Yang, Jaewon; Bahk, Won Myong; Cho, Hyun Sang; Jeon, Yang Whan; Jon, Duk In; Jung, Hee Yeon; Kim, Chan Hyung; Kim, Hee Cheol; Kim, Yong Ku; Kim, Young Hoon; Kwon, Jun Soo; Lee, Sang Yeol; Lee, Seung Hwan; Yi, Jung Seo; Yoon, Bo Hyun; Kim, Seung Hyun.

In: Clinical Neuropharmacology, Vol. 33, No. 4, 01.07.2010, p. 169-175.

Research output: Contribution to journalArticle

Yang, J, Bahk, WM, Cho, HS, Jeon, YW, Jon, DI, Jung, HY, Kim, CH, Kim, HC, Kim, YK, Kim, YH, Kwon, JS, Lee, SY, Lee, SH, Yi, JS, Yoon, BH & Kim, SH 2010, 'Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial', Clinical Neuropharmacology, vol. 33, no. 4, pp. 169-175. https://doi.org/10.1097/WNF.0b013e3181dcda50
Yang, Jaewon ; Bahk, Won Myong ; Cho, Hyun Sang ; Jeon, Yang Whan ; Jon, Duk In ; Jung, Hee Yeon ; Kim, Chan Hyung ; Kim, Hee Cheol ; Kim, Yong Ku ; Kim, Young Hoon ; Kwon, Jun Soo ; Lee, Sang Yeol ; Lee, Seung Hwan ; Yi, Jung Seo ; Yoon, Bo Hyun ; Kim, Seung Hyun. / Efficacy and tolerability of blonanserin in the patients with schizophrenia : A randomized, double-blind, risperidone-compared trial. In: Clinical Neuropharmacology. 2010 ; Vol. 33, No. 4. pp. 169-175.
@article{fcc0f30da3d746ab89bf00651c9b1d5c,
title = "Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial",
abstract = "Objectives: The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. Methods: Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. Results: Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was-23.48 ± 19.73 for the blonanserin group and-25.40 ± 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and increased level blood prolactin (P = 0.0012). On the other hand, the adverse events that occurred more frequently in the blonanserin than in the risperidone group was hand tremor (P = 0.0006). Conclusions: Blonanserin was effective in the treatment of Korean patients with schizophrenia compared with risperidone and was more tolerable with a better safety profile, particularly with respect to prolactin elevation. These findings suggest that blonanserin is useful in the treatment of schizophrenia.",
keywords = "blonanserin, efficacy, schizophrenia, tolerability",
author = "Jaewon Yang and Bahk, {Won Myong} and Cho, {Hyun Sang} and Jeon, {Yang Whan} and Jon, {Duk In} and Jung, {Hee Yeon} and Kim, {Chan Hyung} and Kim, {Hee Cheol} and Kim, {Yong Ku} and Kim, {Young Hoon} and Kwon, {Jun Soo} and Lee, {Sang Yeol} and Lee, {Seung Hwan} and Yi, {Jung Seo} and Yoon, {Bo Hyun} and Kim, {Seung Hyun}",
year = "2010",
month = "7",
day = "1",
doi = "10.1097/WNF.0b013e3181dcda50",
language = "English",
volume = "33",
pages = "169--175",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Efficacy and tolerability of blonanserin in the patients with schizophrenia

T2 - A randomized, double-blind, risperidone-compared trial

AU - Yang, Jaewon

AU - Bahk, Won Myong

AU - Cho, Hyun Sang

AU - Jeon, Yang Whan

AU - Jon, Duk In

AU - Jung, Hee Yeon

AU - Kim, Chan Hyung

AU - Kim, Hee Cheol

AU - Kim, Yong Ku

AU - Kim, Young Hoon

AU - Kwon, Jun Soo

AU - Lee, Sang Yeol

AU - Lee, Seung Hwan

AU - Yi, Jung Seo

AU - Yoon, Bo Hyun

AU - Kim, Seung Hyun

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Objectives: The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. Methods: Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. Results: Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was-23.48 ± 19.73 for the blonanserin group and-25.40 ± 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and increased level blood prolactin (P = 0.0012). On the other hand, the adverse events that occurred more frequently in the blonanserin than in the risperidone group was hand tremor (P = 0.0006). Conclusions: Blonanserin was effective in the treatment of Korean patients with schizophrenia compared with risperidone and was more tolerable with a better safety profile, particularly with respect to prolactin elevation. These findings suggest that blonanserin is useful in the treatment of schizophrenia.

AB - Objectives: The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design. Methods: Patients aged 18 to 65 years with schizophrenia were randomly assigned to blonanserin or risperidone treatment for 8 weeks. The efficacy was assessed using the mean change in Positive and Negative Syndrome Scale score total scores from baseline to week 8. Safety assessments included monitoring of vital signs, a physical examination, laboratory tests, and adverse events. Results: Of 206 randomly enrolled patients, 103 receiving blonanserin and 103 receiving risperidone were included in the analysis. In this study, noninferiority between blonanserin and risperidone was demonstrated. The mean change in the Positive and Negative Syndrome Scale total score at the final evaluation time point was-23.48 ± 19.73 for the blonanserin group and-25.40 ± 18.38 for the risperidone group. Adverse events, which occurred less frequently in the blonanserin than in the risperidone group, included dysarthria (P = 0.0288), dizziness (P = 0.0139), increased alanine aminotransferase and aspartate aminotransferase (P = 0.0095 and P = 0.0032, respectively), and increased level blood prolactin (P = 0.0012). On the other hand, the adverse events that occurred more frequently in the blonanserin than in the risperidone group was hand tremor (P = 0.0006). Conclusions: Blonanserin was effective in the treatment of Korean patients with schizophrenia compared with risperidone and was more tolerable with a better safety profile, particularly with respect to prolactin elevation. These findings suggest that blonanserin is useful in the treatment of schizophrenia.

KW - blonanserin

KW - efficacy

KW - schizophrenia

KW - tolerability

UR - http://www.scopus.com/inward/record.url?scp=77955141217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955141217&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3181dcda50

DO - 10.1097/WNF.0b013e3181dcda50

M3 - Article

C2 - 20661022

AN - SCOPUS:77955141217

VL - 33

SP - 169

EP - 175

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 4

ER -